The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorCoskuner, Taner
dc.contributor.authorCaglayan, Senguel
dc.contributor.authorAkgun, Ozlem
dc.contributor.authorTorun, Ruya
dc.contributor.authorYayla, Emine Nur Sunar
dc.contributor.authorBagrul, Ilknur
dc.contributor.authorKilbas, Gulsah
dc.contributor.authorYener, Gulcin Otar
dc.contributor.authorKose, Hulya
dc.contributor.authorOzturk, Kubra
dc.contributor.authorBaba, Ozge
dc.contributor.authorCakan, Mustafa
dc.contributor.authorDemir, Ferhat
dc.contributor.authorSonmez, Hafize Emine
dc.contributor.authorKalyoncu, Mukaddes
dc.contributor.authorKilic, Sara Nsebnem
dc.contributor.authorYuksel, Selcuk
dc.contributor.authorBaglan, Esra
dc.contributor.authorBakkaloglu, Sevcan A.
dc.contributor.authorUnsal, Erbil
dc.contributor.authorAktay Ayaz, Nuray
dc.contributor.authorSozeri, Betul
dc.date.accessioned2025-10-16T15:14:14Z
dc.date.issued2023
dc.identifier.doi10.1080/14712598.2023.2282133
dc.identifier.otherWOS:001104560100001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6103
dc.publisherTAYLOR \& FRANCIS LTD
dc.sourceEXPERT OPINION ON BIOLOGICAL THERAPY
dc.subjectCanakinumab
dc.subjectsafety
dc.subjectautoinflammatory diseases
dc.subjectsystemic juvenile idiopathic arthritis
dc.titleThe safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS